局限期小细胞肺癌胸部放射治疗的研究进展

doi:10.13481/j.1671-587x.20180138

[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J]. J Clin Oncol,2006,24(28):4539-4544.
[2] Byers LA,Rudin CM.Small cell lung cancer:where do we go from here[J].Cancer,2015,121(5):664-672.
[3] Micke P,Faldum A,Metz T,et al.Staging small cell lung cancer:Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease[J].Lung Cancer,2002,37(3):271-276.
[4] Shepherd FA,Crowley J,Van Houtte P,et al.The International Association for the Study of Lung Cancer lung cancer staging project:proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor,node,metastasis classification for lung cancer[J].J Thorac Oncol,2007,2(12):1067-1077.
[5] Ignatius Ou SH,Zell JA.The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition[J].J Thorac Oncol,2009,4(3):300-310.
[6] Vallières E,Shepherd FA,Crowley J,et al.The IASLC Lung Cancer Staging Project:proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer[J].J Thorac Oncol,2009,4(9):1049-1059.
[7] Goldstraw P,Crowley J,Chansky K,et al.The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J].J Thorac Oncol,2007,2(8):706-714.
[8] Almquist D,Mosalpuria K,Ganti AK,et al.Multimodality therapy for limited-stage small-cell lung cancer[J].J Oncol Pract,2016,12(2):111-117.
[9] Verma V,Simone CB,Zhen W.Stereotactic radiotherapy for stage Ⅰ small cell lung cancer[J].Oncologist,2016,21(2):131-133.
[10] Alvarado-Luna G,Morales-Espinosa D.Treatment for small cell lung cancer,where are we now?-a review[J].Transl Lung Cancer Res,2016,5(1):26-38.
[11] Turrisi AT,Kim K,Blum R,et al.Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J].N Engl J Med,1999,340(4):265-271.
[12] El Sharouni SY,Kal HB,Barten-Van Rijbroek A,et al.Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer:a retrospective comparative study[J].Anticancer Res,2009,29(12):5219-5224.
[13] Pignon JP,Arriagada R,Ihde DC,et al.A meta-analysis of thoracic radiotherapy for small-cell lung cancer[J].N Engl J Med,1992,327(23):1618-1624.
[14] Warde P,Payne D.Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis[J].J Clin Oncol,1992,10(6):890-895.
[15] Pijls-Johannesma M,De Ruysscher D,Vansteenkiste J,et al.Timing of chest radiotherapy in patients with limited stage small cell lung cancer:a systematic review and meta-analysis of randomised controlled trials[J].Cancer Treat Rev,2007,33(5):461-473.
[16] De Ruysscher D,Pijls-Johannesma M,Bentzen SM,et al.Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer[J].J Clin Oncol,2006,24(7):1057-1063.
[17] Murray N,Coy P,Pater JL,et al.Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer.The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1993,11(2):336-344.
[18] De Ruysscher D,Lueza B,Le Péchoux C,et al.Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J].Ann Oncol,2016,27(10):1818-1828.
[19] Lueza B,LePéchoux C,Pignon JP,et al.Phase Ⅲ trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer[J].Ann Oncol,2014,25(9):1865-1866.
[20] 刘维帅,赵路军,关勇,等.局限期小细胞肺癌诱导化疗疗效与放疗时机的关系探讨[J].中国肿瘤临床,2014,41(1):73-77.
[21] De Ruysscher D,Bremer RH,Koppe F,et al.Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer:a phase Ⅱ trial[J].Radiother Oncol,2006,80(3):307-312.
[22] Baas P,Belderbos JS,Senan S,et al.Concurrent chemotherapy (carboplatin,paclitaxel,etoposide) and involved-field radiotherapy in limited stage small cell lung cancer:a Dutch multicenter phase Ⅱ study[J].Br J Cancer,2006,94(5):625-630.
[23] Hu X,Bao Y,Zhang L,et al.Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer:interim analysis of a prospective randomized noninferiority trial[J].Cancer,2012,118(1):278-287.
[24] Xia B,Chen GY,Cai XW,et al.Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer[J]. Radiother Oncol,2012,102(2):258-262.
[25] Faivre-Finn C,Snee M,Ashcroft L,et al.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label,phase 3,randomised,superiority trial[J].Lancet Oncol,2017,18(8):1116-1125.
[26] Ulger S,Demirci NY,Aydinkarahaliloglu E,et al.PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancer[J].J Thorac Dis,2015,7(3):295-302.
[27] Cai S,Shi A,Yu R,et al.Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy[J].Radiat Oncol,2014,9:17.
[28] Zhu L,Zhang S,Xu X,et al.Increased biological effective dose of radiation correlates with prolonged survival of patients with limited-stage small cell lung cancer:A systematic review[J].PLoS One,2016,11(5):e0156494.
[29] Xia B,Chen GY,Cai XW,et al.The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer[J].Radiat Oncol,2011,6:50.
[30] Zahra A,Chang T,Hejleh TA,et al.Once daily high-dose radiation (≥ 60 Gy) treatment in limited stage small cell lung cancer[J].J Oncol Transl Res,2016,2(1).pii:108.
[31] Salama JK,Hodgson L,Pang H,et al.A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy:CALGB 30904[J].J Thorac Oncol,2013,8(8):1043-1049.
[32] Lee KJ,Lee EJ,Hur GY,et al.The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer[J].Korean J Intern Med,2013,28(4):449-455.
[33] Sas-Korczynska B,Sokolowski A,Korzeniowski S.The influence of time of radio-chemotherapy and other therapeutic factors on treatment results in patients with limited disease small cell lung cancer[J].Lung Cancer,2013,79(1):14-19.
[34] Xia B,Hong LZ,Cai XW,et al.Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2015,91(3):517-523.
[35] Yee D,Hanson J,Butts C,et al.Phase Ⅰ dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung[J].Radiother Oncol,2010,96(1):78-83.
[36] Murray N,Coy P,Pater JL,et al.Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer.The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1993,11(2):336-344.
[37] Giuliani ME,Lindsay PE,Sun A,et al.Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma[J].Radiother Oncol,2012,102(2):263-267.
[38] Zhang J,Fan M,Liu D,et al.Hypo-or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer[J].Radiat Oncol,2017,12(1):51.
[39] Videtic GM,Stephans KL.The role of stereotactic body radiotherapy in the management of non-small cell lung cancer:an emerging standard for the medically inoperable patient[J]. Curr Oncol Rep,2010,12(4):235-241.
[40] Shioyama Y,Nakamura K,Sasaki T,et al.Clinical results of stereotactic body radiotherapy for Stage Ⅰ small-cell lung cancer:a single institutional experience[J].J Radiat Res,2013,54(1):108-112.
[41] Videtic GM,Stephans KL,Woody NM,et al.Stereotactic body radiation therapy-based treatment model for stage Ⅰ medically inoperable small cell lung cancer[J].Pract Radiat Oncol,2013,3(4):301-306.
[42] Li C,Xiong Y,Zhou Z,et al.Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer:a single-center prospective phase Ⅱ study[J].Med Oncol,2014,31(12):369.
[43] 丁新民,冯华松,伏婷婷,等.紫杉醇顺铂方案联合同步放疗治疗顺铂依托泊苷化疗不敏感局限期小细胞肺癌的临床疗效[J].中国老年学杂志,2016,36(1):344-346.

Research progress in thoracic radiotherapy in limited-disease small cell lung cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LI Lijing, ZANG Yaru, YU Wenhui, LIANG Junwei, TONG Yanjun. Therapeutic effect of chemotherapy combined with sodium cantharidinate vitamin B6 injection in patientswith non-small cell lung cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1286-1290.
[2]	SUN Hongshuai, ZHU Hua, GAO Haiyan, WAN Guangcai, YU Xiuyan. Value of combined detection of tumor markers SCC-Ag, CEA, CYFRA21-1 and D-dimer in early diagnosis of non-small cell lung cancer [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1020-1024.
[3]	. Research progress in relationships between polymorphisms of DNA damage repair pathway gene and sensitivity and prognosis of non-small cell lung cancer treated with platinum drugs [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 869-874.
[4]	QUAN Xiaoyue, LIU Bailong, LIU Min, DONG Lihua. Treatment of lung squamous cell carcinoma with apatinib in patient who couldn't tolerate chemotherapy: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 624-627.
[5]	LIU Xiangliang, JI Wei, LI Li, ZHAO Yinghua, JIA Lin, WANG Zhiqiang, CHEN Xiao, LI Wei. Lung adenocarcinoma treated by Erlotinib HCL Tablets and chemotherapy combined with bevacizumab after drug resistance:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1019-1024.
[6]	LIU Danqing, YE Shufeng, TONG Weifang, TENG Bo, WANG Sanchun, FENG Qingjie. Renal clear cell carcinoma transferred to nasal cavity and sinuses:A case reportand literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 829-831.
[7]	. Progress research on effect of long non-coding RNA in occurrence and development of lung cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 450-453.
[8]	LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.
[9]	XI Yanli, XU Na, LI Shu, WANG Di, WANG Shuran, NIU Fenglan. Inhibitory effect of gallic acid on proliferation of human non-small cell lung cancer A549 cells [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1092-1098.
[10]	. Progress research on mechanism of FGFR signaling pathway in pathogenesis of IPF and non-small cell lung cancer [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1254-1258.
[11]	LIU Huanxin, ZHANG Guoxiang, GUO Linlang, TAN Songshan. Expression of miR-139-5p in small cell lung cancer tissue and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 942-948.
[12]	YUN Fen, JIA Yongfeng, HAN Zhao, SUN Qinnuan, LI Xiuxia, YU Huiling. Expression of HIF-2αin non-small cell lung cancer tissue and its relationships with MVD,Ki67,and GST-π [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 954-957.
[13]	LI Shimeng, PAN Baoxiang, LI Tong, XIE Feng, WANG Hai. Correlation between expression of programmed cell death-ligand 1 protein and prognosis of lung cancer:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2015, 41(05): 969-973.
[14]	LIN Xing-yu,YANG Zhi-guang,ZHANG Peng,SHAO Guo-guang. Comparison of curative effects of lobectomy between C-VATS  and thoracotomy in aged patients with lung cancer  [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1275-1279.
[15]	ZUO Xiao-jun,NI Guan-ying . Application of 18F-FDG PET-CT in TNM staging of non-small cell lung cancer and clinical significance [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1293-1296.